title: Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
abstract: The urokinase-type plasminogen activator (uPA) system plays an important role in tumor cell invasion, metastases, and angiogenesis. uPA, uPA receptor, and plasminogen activator inhibitor 1 (PAI-1) are prognostic factors in different solid tumors, e.g., renal cell carcinomas (RCCs). von Hippel-Lindau (VHL) disease is an inherited cancer syndrome that is characterized by extensively vascularized tumors, including hemangioblastomas and RCCs. In 75% of sporadic RCCs, the VHL gene is also inactivated. It has been recognized in sporadic RCC that PAI-1 mRNA levels are up-regulated and uPA mRNA levels are down-regulated. We determined the role of the VHL tumor suppressor gene in the regulation of the uPA system in RCC. In 786-O RCC cells expressing the wild-type (wt) VHL gene, we measured a 3-fold higher overall urokinase activity than in 786-O cells expressing a mutant VHL gene or lacking VHL. uPA mRNA and protein levels were higher in cells with wt VHL compared with cells with mutant VHL or lacking VHL. In addition, PAI-1 mRNA and protein levels were dramatically increased in 786-O cells with mutant VHL or lacking VHL, compared with cells expressing wt VHL. Our results provide further evidence that the VHL gene plays an important role in the process of angiogenesis by regulation of plasmin-mediated proteolysis of the extracellular matrix and may explain why VHL-induced RCCs grow slowly and metastasize relatively late.
authors.affiliation: Department of Internal Medicine, Laboratory of Medical Oncology, University Hospital Utrecht, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Los
authors.forename: S
authors.initials: S
authors.lastname: Zeamari
authors.forename: J A
authors.initials: JA
authors.lastname: Foekens
authors.forename: M F
authors.initials: MF
authors.lastname: Gebbink
authors.forename: E E
authors.initials: EE
authors.lastname: Voest
mesh_terms: D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000201:enzymology*; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000098:blood supply / Q000201:enzymology*; D008025:Ligases; D009389:Neovascularization, Pathologic / Q000209:etiology; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D011506:Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000032:analysis; D011956:Receptors, Cell Surface / Q000235:genetics; D055293:Receptors, Urokinase Plasminogen Activator; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*; D051794:Von Hippel-Lindau Tumor Suppressor Protein
chemical_list: C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D011506:Proteins; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D014568:Urokinase-Type Plasminogen Activator; D008025:Ligases; C497446:VHL protein, human; D013755:Tetradecanoylphorbol Acetate